Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial
In line with previously published data, incidences of all-cause mortality and AESIs
were similar in patients given belimumab and placebo, except for serious infusion
or hypersensitivity reactions, serious depression, treatment-emergent suicidality,
and sponsor-adjudicated serious suicide or self-in…
30355-6%2Ffulltext "www.thelancet.com")
www.thelancet.com30355-6/fulltext)